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Abstract
Merkel cell carcinoma (MCC), is a rare, highly
malignant skin tumour, with a poor prognosis. Though the
aetiology of MCC is not known, but there are several features
that it shares with melanoma. These include the natural history,
clinical features and behaviour, e.g. an early spread to nodal
sites, high local recurrence rate and early metastasis.
Incidence of MCC is seen to be increased in immuno-
suppressed transplant patients, in patients with rheumatoid
arthritis and in B cell malignancies, with a strong male
predominance. Despite the ongoing research and advancement,
MCC yet poses a challenge to the clinicians because of its
rarity.
The purpose of this paper is to review the most salient
and clinically relevant updates of MCC since its first
publication in July 2007 in JPMA. In order to expedite an
improved understanding of the new diagnostic modalities,
treatment and preventive measures, along with the new staging
system established in 2009 after an extensive literature review,
and an analysis of over 5,000 patients using the National
Cancer Database has all been included in our article. 
Keywords: Merkel Cell Carcinoma, Skin Cancers,
Radiotherapy, Chemotherapy.
Introduction
Merkel cell carcinoma (MCC) is an aggressive
dermal tumour of neuro-endocrine origin. It is a rare, highly
malignant primary skin tumour, originally called "trabecular
carcinoma" of the skin. Approximately 2000 cases of MCC
have been reported. The annual age-adjusted incidence per
100 000 is 0.23 for white individuals and 0.01 for black
individuals.1
MCC poses a challenge to the clinician because of its
rarity and poor prognosis.2 Toker first described it in 1972.3
Toker had observed that the tumour originates from the
neuroendocrine cells of the basal epidermis of the skin. Merkel
described the cell of the origin as epidermal, non-dendritic,
non-kerotinocytic cell that he referred to as a tactile cell.4
Electron microscopy and immunocytochemical studies are
often required for accurate diagnosis. 
The recently discovered Merkel cell polyomavirus
(MCPyV) harboured in the inflammatory monocytes is said to
be implicated in the oncogenesis of Merkel cell carcinoma
(MCC).5
Clinical Features:
Although this carcinoma is usually found in elderly
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individuals, it can occur in young patient as well. Median
age at presentation is around 67 years. The vast majority of
patients affected by MCC are white. It has strong male
predominance. Most MCCs occur on sun exposed areas of
the body.6
Common sites of the tumour are: Head and neck (47-
50%); Extremities (40%) and Trunk (8%).
The aetiology of MCC is not known. Sun exposure is
considered as one of the risk factors as ultra violet exposure
induced C to T mutation was found in some MMC cell lines.7
The occurrence of MCC has also been reported in HIV infected
patients together with other malignancies. Recent reports have
shown an increased incidence in immuno-suppressed
transplant patients, in rheumatoid arthritis and in B cell
malignancies. 
The natural history of MCC shares many common
features with melanoma.
Like melanoma, MCC is also a cutaneous malignancy
of same embryonic origin. These two malignancies also show
similar clinical features and behaviour, e.g. an early spread to
nodal sites, high local recurrence rate and early metastasis.8
Yom et al from the department of Radiation Oncology,
M.D. Anderson Cancer Centre, Houston suggested that the
differential diagnosis of Merkel cell carcinoma should be
included in patients presenting with mucosal lesions of head
and neck, especially if the tumour is sub-mucosal. MCC can
also involve the tongue. Mucosal MCC is aggressive, and there
is a high risk for local recurrence and regional and distant
metastasis.9
Traditionally, Immunohistochemical markers like
CK20 +, CK7-and-TTF1 are used in order to distinguish
between MCC and other tumours.10
Diagnostic evaluation:
Histologically, the tumour consists of sheets of small
round blue cells, an appearance that is similar to melanoma and
metastatic small cell carcinoma. Immunohistochemical stains
may be used to determine whether the primary tumour is
indeed a primary MCC of the skin or cutaneous metastases
from a visceral small cell carcinoma. 
MCC has immunohistochemical features of both
neuroendocrine and epithelial cells. It is usually positive for
cytokeratin, CK20 (unlike melanoma and metastatic squamous
cell carcinoma), and is usually negative for S100 and thyroid
transcription factor 1 (TTF-1), a newly described nuclear
protein that appears to be specific for small cell carcinoma of
pulmonary origin.1
A report published in Anticancer Research in June 2006
has evaluated the role of cell cycle-regulatory proteins
(p53/p21/p27) in Merkel Cell Carcinoma's pathogenesis and
prognosis. Twenty-four primary MCC specimens with
corresponding clinical data were analysed by
immunohistochemistry for p21, p27 and p53 antibodies. The
staining was evaluated semi-quantitatively and the results were
analysed. p53 was negative in 80% and p21 in 71% of the
samples. Positive staining for p27 was evident in 92% of the
samples. However, the expression of these antibodies did not
correlate with the outcome of the patient. 
The proportion of p53- and p21-negative samples
seems to indicate that correction processes after DNA damage
are not activated during MCC pathogenesis, a supposition that
is supported by the aggressive nature of this tumour. It was
concluded that, the above mentioned three cell cycle regulators
cannot serve as prognostic markers for survival.11
Under the microscope most of the MCC specimens
show a clear Grenz zone separating the epidermis from the
tumour. The immunohistochemistry of MCC exhibits positive
staining to neurofilament, cytokeratin, neuron specific enolase
and epithelial membrane antigen.12
Staging:
Patient with MCC can be staged according to the
American Joint Committee on Cancer (AJCC) staging system
for skin cancer. Alternatively, a relatively simple system was
proposed by Yiengpruksawan et al11 which can be used for
stage grouping:
StageI: patients with localized disease; those with
tumour of less than 2 cm are considered stage 1A, whereas
those with tumour of 2 cm or more are considered as stage 1B.
Stage II: with regional lymph node metastasis 
Stage III: with distant metastasis.
Yiengpruksawan and colleagues have reported that at
the time of first consultation 70% to 80% of patients with MCC
have stage I, 10% to30% have stage II, and 4% to 15% have
stage III disease.
A new MCC staging system has been established in
2009, being based on an extensive literature review, and an
analysis of over 5,000 patients using the National Cancer
Database.
Stages I & II MCC are defined as disease that is
localized to the skin at the primary site. Stage I is for primary
lesions less than or equal to 2 centimeters, and stage II is for
primary lesions greater than 2 cm. Stage III is defined as
disease that involves nearby lymph nodes (regional lymph
nodes). Stage IV disease is found beyond regional lymph
nodes.
In this system, the disease is being divided into stages
depending on the severity of disease. The stage at diagnosis is
a major determinant of the chance for spread (metastasis),
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treatment options and chance for recovery.13
Primary Tumour (T)14
TX: Primary tumour cannot be assessed
T0: No evidence of primary tumour (e.g., nodal/metastatic presentation
without associated primary)
Tis: In situ primary tumour
T1: < 2 cm maximum tumour dimension
T2: >2 cm but < 5 cm maximum tumour dimension
T3: >5 cm maximum tumour dimension
T4: Primary tumour invades bone, muscle, fascia, or cartilage.
Regional Lymph Nodes (N)14
NX: Regional lymph nodes cannot be assessed
N0: No regional lymph nodes metastasis
cN0: Nodes negative by clinical exam (no pathologic node exam performed)
pN0: Nodes negative by pathologic exam
N1: Metastasis in regional lymph node(s)
N1a: Micrometastasis
N1b: Macrometastasis
N2: In transit metastasis.
The following are the definitions of terms used in
AJCC-2010 staging system:
 Clinical detection of nodal disease done via
inspection, palpation, and/or imaging. 
 Micrometastases are diagnosed after sentinel or
elective lymphadenectomy.
Macrometastases are defined as clinically detectable
nodal metastases confirmed by therapeutic lymphadenectomy
or needle biopsy.
 In transit metastasis: a tumour distinct from the
primary lesion and located either (1) between the primary
lesion and the draining regional lymph nodes or (2) distal to the
primary lesion.
Distant Metastasis (M)14
M0: No distant metastasis
M1: Metastasis beyond regional lymph nodes
M1a: Metastasis to skin, subcutaneous tissues or distant lymph nodes
M1b: Metastasis to lung
M1c: Metastasis to all other visceral sites.
Patients with primary Merkel cell carcinoma with no
evidence of regional or distant metastases (either clinically or
pathologically) are divided into two stages: stage I for primary
tumours no more than 2 cm in size and stage II for primary
tumours larger than 2 cm in size. Stage I and stage II are further
divided into A and B substages based on method of nodal
evaluation. Patients who have pathologically proven node
negative disease (by microscopic evaluation of their draining
lymph nodes) have improved survival (substaged as A)
compared with those who are evaluated only clinically
(substaged as B). Stage II has an additional substage (IIC) for
tumours with extracutaneous invasion (T4) and negative node
status regardless of whether the negative node status was
established microscopically or clinically. Stage III is also divided
into A and B categories for patients with microscopically positive
and clinically occult nodes (IIIA) and macroscopic nodes (IIIB).
There are no subgroups of stage IV Merkel cell carcinoma.15
Anatomic Stage/Prognostic Groups14
Stage 0 Tis N0 M0
Stage 1A T1 pN0 M0
Stage 1B T1 cN0 M0
Stage IIA T2/T3 pN0 M0
Stage IIB T2/T3 cN0 M0
Stage IIC T4 N0 M0
Stage IIIA Any T N1a M0
Stage IIIB Any T N1b/N2 M0
Stage IV Any T Any N M1
The Department of Pathology, Memorial Sloan-
Kettering Cancer Center (MSKCC), New York, introduced the
much favoured "4-tiered" or "four - stage" system,16 before the
advent and publication of the new AJCC consensus staging
system. This system was based on the largest number of
patients and was the best validated17 by Andea AA et al.
The stages in the MSKCC system are as follows:
Stage I: local disease <2 cm
Stage II: local disease > 2 cm
Stage III: regional nodal disease
Stage IV: distant metastatic disease.
The prognostic significance of the suggested 12
elements to be described in pathology reports of resected
primary lesions, and the nine elements to be described in
pathology reports of sentinel lymph nodes, has not been
validated prospectively.18
Although immune suppression and ultraviolet radiation
have long been associated with the MCC oncogenesis, recent
studies also show involvement of a new polyomavirus and bcl-
2.16 Several tumour classifications have been published in the
literature, with the 4-tiered system from Memorial Sloan-
Kettering Cancer Center the most widely used. 
Management: 
MCC is a rare tumour and all information pertaining to
its behaviour, therapy and prognosis is based on retrospective
reports. The two potentially curative treatment modalities are
surgery and radiotherapy. The optimal therapy is individualised
in any given patient with the appropriate use of operative
resection and radiation therapy. Several authors reported that
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postoperative radiotherapy to the primary tumour and regional
lymphatic significantly improves local control and disease free
survival.19
MCC has a poor prognosis, with 5-year survival of
30% to 68%.13,20-23
It was only a single study by Allen PJ, et al.,13 in which
a review of the Memorial Sloan-Kettering Cancer Center's
MCC database was performed, having identified 251 patients
who had been treated between 1970 and 2002. Patient, tumour,
and treatment-related factors were analyzed for their
association with recurrence and survival, but no association
was found between irradiation and locoregional contro.13
In a retrospective analysis of tumour registries from the
6 hospitals of the Scripp's Health facilities, California, USA,24
twenty-two patients were identified over the last decade, after
review of their Hospital and clinic charts along with their
pathology specimens. Amongst these, eight patients underwent
Mohs' surgery with no subsequent local recurrence; however,
out of the six patients who received adjuvant radiation therapy,
only one of them developed disease recurrence within the
radiation field. Seven patients received systemic
chemotherapy, whereas one denied treatment after a punch
biopsy.24
Another collaborative retrospective study of 45 MCC
patients, from the National Naval Medical Center, Bethesda;
Shadyside Hospital, Pittsburgh; and Pittsburgh Cancer
Institute,25 is being published in the Journal of American
Academy of Dermatology. Patients with stage I disease were
found to be histologically and clinically disease free after
Moh's excision. Subsequent radiation was given electively to
the primary site in 20 patients, whereas 25 patients did not
receive any adjuvant radiation therapy. Consequently, one
marginal recurrence (4%) and 3 in-transit metastases were
observed in the Moh's surgery alone group, whereas none were
observed in the Moh's surgery and radiation group.25
In the context of the two above mentioned studies, it
was finally concluded that Mohs' surgical technique combined
with radiation therapy provided excellent local control.
Adjuvant radiation appears unessential to secure local control
of primary MCC lesions, completely excised with Moh's
micrographic surgery. Adjuvant radiation is recommended for
patients who are unable to have complete excision, or if
complete histologic margin control is unavailable, and should
be considered for patients with large or recurrent tumours. As
such, the role of irradiation after Moh's surgery is not very
clear.24,25
However, recent data suggest an association between
the use of radiation and overall survival. Mojica et al26
retrospectively analyzed the Surveillance, Epidemiology, and
End Results (SEER) database from the National Cancer
Institute from 1973 to 2002, and found a significant association
between the use of radiation and survival.
The mainstay of treatment is wide local excision of
tumour with reconstructive surgery.27
Management of primary lesion with clinically localised
disease is wide excision with a margin of at least 2 cm
whenever possible. The excision should include the skin and
subcutaneous tissue. Resection of the underlying fascia is also
performed when the tumour is close to it. Excision margins of
less than 3cm are associated with high incidence of local
failures.28 Due to high incidence of nodal metastasis,
prophylactic lymphadenectomy is also suggested in some
reports, alternatively sentinel node biopsy can be considered as
an appropriate procedure in clinically node negative patient.
Approximately 25% of patients found to have metastatic
disease in the sentinel node biopsy. Early removal of
microscopic disease detected by this diagnostic approach may
offer the patient a greater opportunity for cure.29 It is often
difficult or impossible to excise MCC of the head and neck or
distal extremity with a wide margin. Adjuvant radiotherapy can
be considered in these cases. If the primary cancer is to be
treated with radiotherapy alone, the regional lymphatic may be
electively irradiated. Patient who present with fixed,
unresectable nodal metastasis are treated with preoperative
radiotherapy followed by salvage surgery of the primary site
with a possible nodal dissection.
MCC is a radiosensitive tumour, adjuvant radiotherapy
has been advocated in order to control local as well as regional
disease.19 Radiation induced toxicity should be considered and
discussed with the patient. Adjuvant radiation to the nodal bed
after complete lymphadenectomy in patients with metastatic
disease is generally not recommended. Regional recurrence is
uncommon after a complete lymphadenectomy is performed in
patients who had positive sentinel node biopsy.29 On the other
hand in patients with clinically proven regional disease
adjuvant radiation treatment improves regional control.
There is no established dose response curve for the
MCC. It is quite likely that its response to radiation is similar
to that observed in squamous cell carcinoma. Therefore, the
dose fractionation schedule for patients with negative surgical
margin is of the order of 60 Gray in 30 fractions over 6 weeks
or equivalent.30
Systemic chemotherapy is recommended in patients
with regional or systemic metastasis as a palliative measure. It
gives 50% to 60% palliative response rate which is found to be
more evident in patients with regional disease and less for
visceral metastases. The use of various chemotherapeutic
agents, both single and in combination, are reported in the
literature. Agents like cyclophosphamide, doxorubicine,
vincristine, etoposide, cisplatin, carboplatin, octreotide and
dacarbazine have shown some palliative benefits.31 The option
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of systemic chemotherapy should be offered to patients who
present with nodal or metastatic disease.32
A meta-analysis was published in Archives of
Dermatology, June 2006 issue. Lewis et al2 of Veterans Affairs
Medical Centre, Providence performed an Ovid Medline
search covering published articles from January 1966 to May
2004. The search yielded 242 discrete citations. Reports from
all 242 citations were reviewed. Further ,601 citations,
abstracts were reviewed to assess the level of relevance for
potential inclusion; reports from 63 of these citations were
reviewed. An additional 28 secondary references were
reviewed, for a total of 333 reports. A total of 1254 patients
were included in the analysis. Statistically significant
reductions in local (hazard ratio [HR], 0.27; P < .001) and
regional (HR, 0.34; P < .001) recurrence were observed among
patients treated with combination therapy compared with
surgery alone.
Similar rates of distant metastasis were observed
between treatment groups (HR, 0.79; P =.31). Overall survival
rates were 87% (1 year) and 49% (5 years).Cause-specific
survival rates were 90% (1 year) and 62% (5 year). In general,
differences in overall (HR, 0.78; P = 0.16) and cause-specific
(due to MCC: HR, 0.72; P = .14) survival rates between
treatment groups did not reach statistical significance. A
subgroup analysis that excluded single-patient case reports and
studies of only 1 treatment group revealed a significant overall
(HR, 0.63; P =0.02) and cause-specific (HR, 0.62; P = .04)
survival advantage after treatment with combination therapy. 
It was concluded that surgery plus adjuvant irradiation
was associated with significantly lower rates of local and
regional recurrence of MCC than surgery alone. Prospective
investigation is needed to clarify the presence of a survival
benefit from combination therapy.2
Swann and Yoon33 have done a review of MCC which
is published in the Seminars of Oncology in February 2007.
They have drawn some pertinent conclusions on the prognosis
and management of MCC. The prognosis of MCC is variable.
Natural history of localized disease is indolent and these
tumours are well controlled with local excision alone. On the
other side of the spectrum, majority of tumours behave
aggressively and have a tendency for locoregional recurrence
and distant metastases. In locally advanced and metastatic
disease the option of systemic chemotherapy with regimens
similar to those which are used in the treatment of small cell
carcinoma of the lung, may be considered in adjuvant setting
following surgery.33
MCC is characterized by a high incidence of local and
regional recurrence. Long term survival with low incidence of
recurrence is reported in patients with early stage of the tumour.
Most recurrences occur in the first 24 months and frequent
follow up during this period is recommended. Patients who
develop a local recurrence after primary excision (regardless of
site) should undergo re-excision, if possible, and adjuvant
radiotherapy should be considered if not previously given. The
long survival can be achieved after the treatment of loco
regional recurrence. Voog and colleagues have reported that
patients with loco-regional relapse and distant metastasis had 2
year survival rate of 35% and 17% respectively, versus 86%
and 100% respectively for those who do not have these two
forms of recurrences. The median overall survival after starting
chemotherapy was 9 months for patients with distant
metastasis and 24 months for patient with loco regional
disease.31 The role of immunotherapy is not fully defined.
Immunotherapeutic agents such as alpha- interferon or
intralesional application of tumour necrosis factor-alpha were
shown to have some effects in some patients.34,35
Sandel HD et al36 from the Department of Head and
Neck Surgery, Georgetown University Hospital, Washington
DC conducted a retrospective study and literature review in
order to compare the clinical and histopathological criteria
including tumour size and depth of invasion with clinical
outcomes in MCC patients. The state cancer registry provided
patients records (n = 46) diagnosed with Merkel cell carcinoma
from 1992 to 2002. Pathology slides were reviewed for tumour
size, depth of invasion, Clark level, and marginal status.
Disease-free survival rates were found to be 52%, 39%, and
9% at 1, 2, and 5 years, respectively. The average disease-free
interval was 18.4 months (range, 1-80 months). No correlation
was found between tumour size (P =0.49), depth (P = 0.41), or
Clark level (P = 0.82) to overall survival. A trend was found
comparing tumour size or depth of invasion with local
recurrence (P =0.07) but with no correlation to regional
recurrence (P =0.93 and P = 0.60) or distant metastasis (P =
0.16 and P = 0.24). Overall recurrence was found in 60.7% of
patients with local recurrence occurring in 18.1%, regional
recurrence 40.9%, and distant recurrence 47.8%. Comparing
patients with positive versus negative margins at initial
excision, local recurrence was found in 33.3% versus 9.09% (P
= 0.19), regional recurrence 66.6% versus 27.2% (P = 0.08),
and distant metastasis 66.6% versus 45.4% (P = 0.36),
respectively. No correlation was found between tumour sizes
or depth of invasion to patient survival or metastasis.However,
there was a trend toward increased local and regional
recurrence rates when comparing size and depth and in
specimens with positive tumour margins.36
These outcomes are consistent with those reported in
recent literature and further characterize the unpredictable
nature of this disease. An aggressive approach should be taken,
including wide local excision with negative tumour margins
and lymph node dissection.
Ortin Parez et al37 have reported eight cases of MCC
who underwent sentinel node biopsy. All sentinel nodes were
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successfully harvested. Three patients (37.5%) showed
metastatic involvement and they were subjected to regional
lymphadenectomy.This report published in the European
Journal of Surgical Oncology in February 2007 suggested that
sentinel node biopsy appears to be a reliable staging technique
which can be considered in the surgical management of
MCC.37
A retrospective review was published in the Journal of
Surgical Oncology in March 2007.38 The review of 38
consecutive patients with surgically treated extremity MCC
was presented. Surgical techniques of Wide local excision and
Mohs' surgery was compared. No difference in local recurrence
was found between the two procedures. A reduced local
recurrence rate was observed in patients who were treated by
adjuvant radiotherapy with a hazard ratio of 0.29 (95%
Confidence Interval [0.10, 0.85]).
It has no impact on overall survival. This retrospective
review further supports the rationale of using adjuvant
radiation therapy in improving locoregional tumour control in
MCC patients.38
The rationale of giving External beam radiation therapy
is very well established. Matthew Foote et al.,39 in a clinical
investigation, reported a retrospective analysis of 112 MCC
patients, diagnosed between January 2000 and December
2005, and treated with curative-intent RT. With a median
follow-up of 3.7 years, the 2-year and 5-year overall survival
rates were 72% and 53%, respectively, and the 2-year
locoregional control rate was 75%. Patients who did not
receive elective nodal RT had a much higher rate of nodal
relapse compared with those who did (HR = 6.03; 95% CI,
1.34-27.10).
It was therefore concluded that a dose-response existed
for subclinical and gross MCC, with doses of ?50Gy for
subclinical disease, and > 55Gy for gross disease to be
considered. The draining nodal basin should also be treated in
all patients.39
In the 1st February 2010 issue of the International
Journal of Radiation Oncology, Biology and
Physics(IJROBP),40 a review of 60 cases of MCC of lower
limb has been published. The authors have concluded that
radiotherapy improves relapse free survival when compared
with surgery alone. It is recommended that elective treatment
should be given to the inguinal nodes in order to reduce the risk
of relapse.40
A retrospective analysis of 112 patients of MCC has
recently been published in IJROBP, July 2010 issue.39 The
authors have tried to quantify the radiation dosage required for
the control of subclinical and gross diseases. According to the
recommendation, a dose for subclinical MCC of more than or
equal to 50 Gy should be considered in order to achieve a
response. For gross disease, 55 Gy or more should be
considered. The draining nodal basin should be treated in all
patients.39
Conclusion
Merkel cell carcinoma (MCC) is an aggressive dermal
tumour of neuro-endocrine origin. It is a rare and  highly
malignant primary skin tumour. As described in this review
article muti modality  customised management is planned for
an individual patient of MCC. It is advisable to discuss cases in
a multi-disciplinary expert panel tumour board before
embarking on the first modality of treatment.
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